Recent advances in the systemic treatment landscape have considerably improved disease control in the metastatic setting and led to better oncological outcomes, particularly in human epidermal growth factor receptor 2-positive (HER2+) and hormone receptor-positive (HR+) breast cancer [6,7,8]. The gene discussed is ERBB2; the disease is breast carcinoma.